{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:31:54Z","timestamp":1792146714851,"version":"4.4.0"},"reference-count":42,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n \n Controlled clinical laboratory studies have shown that cannabidiol (CBD) can sometimes attenuate or exacerbate the effects of\n \u0394<\/jats:bold>\n 9-tetrahydrocannabinol (\n \u0394<\/jats:bold>\n 9-THC). No studies have evaluated differences in pharmacokinetics (PK) of\n \u0394<\/jats:bold>\n 9-THC and pharmacodynamics (PD) between orally administered cannabis extracts that vary with respect to\n \u0394<\/jats:bold>\n 9-THC and CBD concentrations.\n <\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n \n To compare the PK and PD of orally administered\n \u0394<\/jats:bold>\n 9-THC-dominant and CBD-dominant cannabis extracts that contained the same\n \u0394<\/jats:bold>\n 9-THC dose (20 mg).\n <\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This randomized clinical trial was a within-participant, double-blind, crossover study conducted from January 2021 to March 2022 at the Johns Hopkins University Behavioral Pharmacology Research Unit, Baltimore, MD. Eighteen healthy adults completed 3 randomized outpatient experimental test sessions that were each separated by at least 1 week.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n \n Brownies containing (1) no cannabis extract (ie, placebo); (2)\n \u0394<\/jats:bold>\n 9-THC-dominant extract (20 mg\n \u0394<\/jats:bold>\n 9-THC with no CBD); and (3) CBD-dominant extract (20 mg\n \u0394<\/jats:bold>\n 9-THC + 640 mg CBD) were administered to participants 30 minutes prior to administering a cytochrome P450 (CYP) probe drug cocktail, which consisted of 100 mg caffeine, 20 mg omeprazole, 25 mg losartan, 30 mg dextromethorphan, and 2 mg midazolam.\n <\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n \n Change-from-baseline plasma concentrations for\n \u0394<\/jats:bold>\n 9-THC or\n \u0394<\/jats:bold>\n 9-THC metabolites and scores for subjective drug effects, cognitive and psychomotor performance, and vital signs. The area under the plasma vs concentration vs time curve (AUC) and maximum plasma concentration (C\n max<\/jats:sub>\n ) were determined.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The participant cohort of 18 adults included 11 males (61.1%) and 7 females (38.9%) with a mean (SD) age of 30 (7) years who had not used cannabis for at least 30 days prior to initiation of the study (mean [SD] day since last cannabis use, 86 [66] days). The CYP cocktail + placebo brownie and the CYP cocktail did not affect any PD assessments. Relative to CYP cocktail\u2009+\u2009\n \u0394<\/jats:bold>\n 9-THC, CYP cocktail\u2009+\u2009\n \u0394<\/jats:bold>\n 9-THC\u2009+\u2009CBD produced a higher C\n max<\/jats:sub>\n and area under the plasma concentration vs time curve for\n \u0394<\/jats:bold>\n 9-THC, 11-OH-\n \u0394<\/jats:bold>\n 9-THC, and\n \u0394<\/jats:bold>\n 9-THC-COOH. The CYP cocktail\u2009+\u2009\n \u0394<\/jats:bold>\n 9-THC\u2009+\u2009CBD increased self-reported anxiety, sedation, and memory difficulty, increased heart rate, and produced a more pronounced impairment of cognitive and psychomotor performance compared with both CYP cocktail\u2009+\u2009\u03949-THC and CYP cocktail\u2009+\u2009placebo.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n \n In this randomized clinical trial of oral\n \u0394<\/jats:bold>\n 9-THC and CBD, stronger adverse effects were elicited from a CBD-dominant cannabis extract compared with a\n \u0394<\/jats:bold>\n 9-THC-dominant cannabis extract at the same\n \u0394<\/jats:bold>\n 9-THC dose, which contradicts common claims that CBD attenuates the adverse effects of\n \u0394<\/jats:bold>\n 9-THC. CBD inhibition of\n \u0394<\/jats:bold>\n 9-THC and 11-OH-\n \u0394<\/jats:bold>\n 9-THC metabolism is the likely mechanism for the differences observed. An improved understanding of cannabinoid-cannabinoid and cannabinoid-drug interactions are needed to inform clinical and regulatory decision-making regarding the therapeutic and nontherapeutic use of cannabis products.\n <\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n clinicaltrials.gov Identifier:\n NCT04201197<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.54752","type":"journal-article","created":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T11:01:43Z","timestamp":1676286103000},"page":"e2254752","source":"Crossref","is-referenced-by-count":97,"title":["Assessment of Orally Administered \u03949-Tetrahydrocannabinol When Coadministered With Cannabidiol on \u03949-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial"],"prefix":"10.1001","volume":"6","author":[{"given":"C. Austin","family":"Zamarripa","sequence":"first","affiliation":[{"name":"Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tory R.","family":"Spindle","sequence":"additional","affiliation":[{"name":"Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renuka","family":"Surujunarain","sequence":"additional","affiliation":[{"name":"Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise M.","family":"Weerts","sequence":"additional","affiliation":[{"name":"Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Bansal","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jashvant D.","family":"Unadkat","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle"},{"name":"Center of Excellence for Natural Product Drug Interaction Research, Spokane, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary F.","family":"Paine","sequence":"additional","affiliation":[{"name":"Center of Excellence for Natural Product Drug Interaction Research, Spokane, Washington"},{"name":"Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Vandrey","sequence":"additional","affiliation":[{"name":"Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,2,13]]},"reference":[{"issue":"7","key":"zoi221549r2","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/jcph.1387","article-title":"A review of human studies assessing cannabidiol\u2019s (CBD) therapeutic actions and potential.","volume":"59","author":"White","year":"2019","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"zoi221549r3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s42238-021-00061-5","article-title":"Reasons for cannabidiol use: a cross-sectional study of CBD users, focusing on self-perceived stress, anxiety, and sleep problems.","volume":"3","author":"Moltke","year":"2021","journal-title":"J Cannabis Res"},{"issue":"1","key":"zoi221549r4","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/0014-2999(74)90129-0","article-title":"Cannabidiol interferes with the effects of delta 9 - tetrahydrocannabinol in man.","volume":"28","author":"Karniol","year":"1974","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"zoi221549r5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/0269881112460109","article-title":"Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment.","volume":"27","author":"Englund","year":"2013","journal-title":"J Psychopharmacol"},{"issue":"9","key":"zoi221549r6","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1007\/s00213-019-05246-8","article-title":"Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition.","volume":"236","author":"Arkell","year":"2019","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"zoi221549r7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00406-019-00978-2","article-title":"A randomised controlled trial of vaporised ?9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects.","volume":"269","author":"Solowij","year":"2019","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"2","key":"zoi221549r8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/BF00434409","article-title":"Intercannabinoid and cannabinoid-ethanol interactions on human performance.","volume":"71","author":"Bird","year":"1980","journal-title":"Psychopharmacology (Berl)"},{"issue":"8","key":"zoi221549r9","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1038\/npp.2015.367","article-title":"Oral cannabidiol does not alter the subjective, reinforcing or cardiovascular effects of smoked cannabis.","volume":"41","author":"Haney","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"zoi221549r10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.drugalcdep.2016.11.030","article-title":"Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers.","volume":"172","author":"Babalonis","year":"2017","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"zoi221549r11","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1097\/01.ftd.0000177223.19294.5c","article-title":"Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract.","volume":"27","author":"Nadulski","year":"2005","journal-title":"Ther Drug Monit"},{"issue":"5","key":"zoi221549r12","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s00228-012-1441-0","article-title":"A phase I study to assess the single and multiple dose pharmacokinetics of THC\/CBD oromucosal spray.","volume":"69","author":"Stott","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"zoi221549r13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40429-022-00429-4","article-title":"Factors that impact the pharmacokinetic and pharmacodynamic effects of cannabis: a review of human laboratory studies.","volume":"9","author":"Zamarripa","year":"2022","journal-title":"Curr Addict Rep"},{"issue":"17","key":"zoi221549r14","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1001\/jama.2017.11909","article-title":"Labeling accuracy of cannabidiol extracts sold online.","volume":"318","author":"Bonn-Miller","year":"2017","journal-title":"JAMA"},{"issue":"24","key":"zoi221549r15","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1001\/jama.2015.6613","article-title":"Cannabinoid dose and label accuracy in edible medical cannabis products.","volume":"313","author":"Vandrey","year":"2015","journal-title":"JAMA"},{"issue":"5","key":"zoi221549r16","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1097\/JCP.0000000000001089","article-title":"The potential for pharmacokinetic interactions between cannabis products and conventional medications.","volume":"39","author":"Qian","year":"2019","journal-title":"J Clin Psychopharmacol"},{"key":"zoi221549r17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.pharmthera.2019.05.001","article-title":"A marijuana-drug interaction primer: precipitants, pharmacology, and pharmacokinetics.","volume":"201","author":"Cox","year":"2019","journal-title":"Pharmacol Ther"},{"issue":"2","key":"zoi221549r18","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/epi.2019.60.issue-2","article-title":"Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial.","volume":"60","author":"Devinsky","year":"2019","journal-title":"Epilepsia"},{"issue":"10125","key":"zoi221549r19","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.","volume":"391","author":"Thiele","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"zoi221549r20","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications.","volume":"57","author":"Mangoni","year":"2004","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"zoi221549r21","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/epi.13060","article-title":"Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy.","volume":"56","author":"Geffrey","year":"2015","journal-title":"Epilepsia"},{"issue":"1","key":"zoi221549r22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s42238-021-00073-1","article-title":"Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: results of a modified Delphi process.","volume":"3","author":"Bhaskar","year":"2021","journal-title":"J Cannabis Res"},{"issue":"4","key":"zoi221549r24","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1124\/dmd.121.000734","article-title":"Comprehensive predictions of cytochrome P450 (P450)-mediated in vivo cannabinoid-drug interactions based on reversible and time-dependent P450 inhibition in human liver microsomes.","volume":"50","author":"Bansal","year":"2022","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"zoi221549r25","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1124\/dmd.120.000073","article-title":"Predicting the potential for cannabinoids to precipitate pharmacokinetic drug interactions via reversible inhibition or inactivation of major cytochromes P450.","volume":"48","author":"Bansal","year":"2020","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"zoi221549r26","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/sj.clpt.6100187","article-title":"Development of the \u201cInje cocktail\u201d for high-throughput evaluation of 5 human cytochrome P450 isoforms in vivo.","volume":"82","author":"Ryu","year":"2007","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"zoi221549r27","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.4841","article-title":"Acute effects of smoked and vaporized cannabis in healthy adults who infrequently use cannabis: a crossover trial.","volume":"1","author":"Spindle","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"4","key":"zoi221549r28","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1093\/jat\/bkx102","article-title":"Pharmacokinetic characterization of 11-nor-9-carboxy-d9-tetrahydrocannabinol in urine following acute oral cannabis ingestion in healthy adults.","volume":"42","author":"Schlienz","year":"2018","journal-title":"J Anal Toxicol"},{"issue":"20","key":"zoi221549r29","doi-asserted-by":"publisher","first-page":"10183","DOI":"10.1021\/acs.analchem.5b02603","article-title":"Analysis of cannabinoids and their metabolites in human urine.","volume":"87","author":"Wei","year":"2015","journal-title":"Anal Chem"},{"issue":"5","key":"zoi221549r30","doi-asserted-by":"publisher","first-page":"485","DOI":"10.4155\/bio-2016-0281","article-title":"Rapid quantification of free and glucuronidated THCCOOH in urine using coated well plates and LC-MS\/MS analysis.","volume":"9","author":"H\u00e4dener","year":"2017","journal-title":"Bioanalysis"},{"issue":"6","key":"zoi221549r31","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/BF01062108","article-title":"Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level\u2013time curve.","volume":"6","author":"Chiou","year":"1978","journal-title":"J Pharmacokinet Biopharm"},{"issue":"2","key":"zoi221549r32","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/jat\/bkx012","article-title":"Pharmacokinetic profile of oral cannabis in humans: blood and oral fluid disposition and relation to pharmacodynamic outcomes.","volume":"41","author":"Vandrey","year":"2017","journal-title":"J Anal Toxicol"},{"issue":"8","key":"zoi221549r33","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1093\/jat\/bkv082","article-title":"Plasma cannabinoid pharmacokinetics after controlled smoking and ad libitum cannabis smoking in chronic frequent users.","volume":"39","author":"Lee","year":"2015","journal-title":"J Anal Toxicol"},{"issue":"3","key":"zoi221549r35","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.euroneuro.2014.11.014","article-title":"Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users.","volume":"25","author":"Hindocha","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"zoi221549r36","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41398-018-0191-x","article-title":"Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function.","volume":"8","author":"Morgan","year":"2018","journal-title":"Transl Psychiatry"},{"issue":"12","key":"zoi221549r37","doi-asserted-by":"publisher","first-page":"890","DOI":"10.7326\/M18-1681","article-title":"Smoking, vaping, and use of edibles and other forms of marijuana among US adults.","volume":"169","author":"Steigerwald","year":"2018","journal-title":"Ann Intern Med"},{"key":"zoi221549r38","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.576877","article-title":"Effects of cannabidiol and delta-9-tetrahydrocannabinol on emotion, cognition, and attention: a double-blind, placebo-controlled, randomized experimental trial in healthy volunteers.","volume":"11","author":"Woelfl","year":"2020","journal-title":"Front Psychiatry"},{"issue":"10","key":"zoi221549r39","doi-asserted-by":"publisher","first-page":"974","DOI":"10.2174\/1570159X17666190603171901","article-title":"Cannabidiol adverse effects and toxicity.","volume":"17","author":"Huestis","year":"2019","journal-title":"Curr Neuropharmacol"},{"issue":"10","key":"zoi221549r40","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1172\/JCI107431","article-title":"Comparative pharmacology of delta9-tetrahydrocannabinol and its metabolite, 11-oh-delta9-tetrahydrocannabinol.","volume":"52","author":"Lemberger","year":"1973","journal-title":"J Clin Invest"},{"key":"zoi221549r41","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.drugalcdep.2013.12.013","article-title":"Investigation of sex-dependent effects of cannabis in daily cannabis smokers.","volume":"136","author":"Cooper","year":"2014","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"zoi221549r42","doi-asserted-by":"publisher","DOI":"10.1111\/adb.v26.4","article-title":"Sex differences in the acute effects of oral and vaporized cannabis among healthy adults.","volume":"26","author":"Sholler","year":"2021","journal-title":"Addict Biol"},{"key":"zoi221549r34","volume-title":"Problems of Drug Dependence","author":"Felch","year":"1996"},{"key":"zoi221549r1","unstructured":"Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2020 National Survey on Drug Use and Health. US Department of Health and Human Services. Accessed January 4, 2022. https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt35325\/NSDUHFFRPDFWHTMLFiles2020\/2020NSDUHFFR1PDFW102121.pdf"},{"key":"zoi221549r23","unstructured":"Epidolex (cannabidiol) prescribing information. US Food and Drug Administration. 2018. Accessed January 17, 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210365lbl.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2801352\/zamarripa_2023_oi_221549_1675372754.033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T11:01:48Z","timestamp":1676286108000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2801352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,13]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.54752","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,13]]}}}